2015年髓系肿瘤研究进展

doi:10.3969/j.issn.1004-583X.2016.02.005

临床荟萃 ›› 2016, Vol. 31 ›› Issue (2): 151-155.doi: 10.3969/j.issn.1004-583X.2016.02.005

2015年髓系肿瘤研究进展

任金海,郭晓楠,郭晓玲,蔡圣鑫

河北医科大学第二医院血液科河北省血液病研究所,河北石家庄 050000

收稿日期:2016-01-11 出版日期:2016-02-05 发布日期:2016-04-18
通讯作者: 任金海,Email:jinhai1966@sina.cn
作者简介:任金海,现任河北医科大学第二医院血液科副主任,主任医师,教授,硕士研究生导师。医学博士。1990年毕业于河北医学院临床医学系,曾先后在中国医学科学院血液病研究所及日本长野赤十字病院进修学习。社会兼职有中国免疫学会血液免疫专业委员会委员;中华血液学会红细胞疾病学组委员;河北省免疫学会血液免疫专业委员会主任委员;河北省医学会血液学分会侯任主任委员;河北省医学会内科学分会委员;河北省实验血液学会理事;河北省肿瘤学会淋巴瘤专业委员会委员。以第一作者及通讯作者发表中英文论文48篇,主编、副主编及参编著作9部,获河北省科技进步三等奖三项,河北省卫生厅优秀医学成果一等奖一项,二等奖二项。培养硕士研究生20余名。擅长髓系肿瘤及各种血液疾病的临床诊断及治疗。

Research advances of myeloid neoplasmas in 2015

Ren Jinhai, Guo Xiaonan, Guo Xiaoling, Cai Shengxin

Department of Haematology,the Second Hospital of Hebei Medical University, Haematology Institute of Hebei Province,Shijiazhuang 050000,China

Received:2016-01-11 Online:2016-02-05 Published:2016-04-18
Contact: Ren Jinhai, Email:jinhai1966@sina.cn

摘要/Abstract

摘要： 本文主要介绍2015年髓系肿瘤的研究进展。包括急性髓系白血病(Acute myeloid leukemia,AML)的分子靶向治疗的研究进展;骨髓增生异常综合征(Myelodysplastic syndrome,MDS)新的分型建议、精准诊断和预后分层以及治疗进展;原发骨髓纤维化(Primary myelofibrosis,PMF)的预后分类系统以及治疗策略。

关键词: 白血病, 髓样, 骨髓增生异常综合征, 原发性骨髓纤维化, 分子靶向治疗

Abstract: The research advances of myeloid neoplasms in 2015 will be introduced,such as new molecularly targeted therapies for acute myeloid leukemia(AML),reclassifying myelodysplastic syndromes(MDS),precise diagnosis and risk assessment of MDS,novel therapeutic approaches of MDS,refining risk stratification and treatment strategy in primary myelofibrosis.

Key words: leukemia, myeloid, myelodysplastic syndromes, primary myelofibrosis , molecularly targeted therapy

中图分类号:

R551.3

任金海,郭晓楠,郭晓玲,蔡圣鑫. 2015年髓系肿瘤研究进展[J]. 临床荟萃, 2016, 31(2): 151-155.

Ren Jinhai, Guo Xiaonan, Guo Xiaoling, Cai Shengxin. Research advances of myeloid neoplasmas in 2015[J]. Clinical Focus, 2016, 31(2): 151-155.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.02.005

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I2/151

参考文献

[1] Burnett A,Wetzler M,Lowenberg B.Therapeutic advances in acute myeloid leukemia[J].J Clin Oncol,2011,29(5):487-494.
[2] Dombret H,Seymcur JF,Butrym A,et al.International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with>30% blasts[J].Blood,2015,126(3):291-299.
[3] Levis M.FLT3 mutations in acute myeloid leukemia:what is the best approach in 2013[J] Hematology AM Soc Hematol Educ Program,2013,2013(1):220-226.
[4] Cortes JE,Kantarjian H,Foran JM,et al.Phase Ⅰ study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status[J].J Clin Oncol,2013,31(29):3681-3687.
[5] Levis MJ,Perl AE,Dombret H,et al.Final results of a phase 2 open-label,monotherapy efficacy and safety study of quizartinib(AC220) in patients with FLT3-ITD positive or negtive relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation[C].ASH Annual Meeting Abstracts,2012,120(21):Abstract 673.
[6] Cortes JE,Perl AE,Dombret H,et al. Final results of a phase 2 open-label,monotherapy efficacy and safety study of quizartinib(AC220) in patients≥60 years of age with FLT3-ITD positive or negtive relapsed/refractory acute myeloid leukemia[C].ASH Annual Meeting Abstracts,2012,120(21):Abstract 48.
[7] Schiller GJ,Tallman MS,Goldberg SL,et al. Final results of a randomized phase 2 study showing the clinical benefit of quizartinib(AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia[J].J Clin Oncol,2014,32:5s(Suppl).Abstract 7100.
[8] Randhawa JK,Kantarjian HM,Borthakur G,et al.Results of phase Ⅱ study of Crenolanib in relapsed/refractory acute myeloid leukemia patients with activating FLT3 mutations[J].Blood,2014,124(21):389.
[9] Levis MJ,Pearl AE,Altman JK,et al.Results of a first-in-human,phase Ⅰ/Ⅱ trial of ASP-2215,a selective,potent inhibitor of FLT3/AXL in patients with relapsed or refractory(R/R) acute myeloid leukemia(AML)[J]. J Clin Oncol,2015,33(Suppl).Abstract 7003.
[10] Lu C,Ward PS,Kapoor GS,et al.IDH mutation impairs histone demethylation and results in a block to cell differentiation[J].Nature,2012,483(7390):474-478.
[11] Chan SM,Thomas D,Corces-Zimmerman MR,et al.Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia[J].Nat Med,2015,21(2):178-184.
[12] Della Porta MG,Thavaglino E,Boveri E,et al.Minimal morphological criteria for defining bone marrow dysplasia:a basis for cinical implementation of WHO classification of myelodysplastic syndromes[J].Leukemia,2015,29(1):66-75.
[13] Maassen A,Strupp C,Giagounidis A,et al.Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts[J].Leuk Res,2013,37(1):64-70.
[14] Valcarcel D,Adema V,Sole F,et al.Complex,not monosomal,karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome[J].J Clin Oncol,2013,31(7):916-922.
[15] Gerstung M,Pellagatti A,Malcovati L,et al.Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes[J].Nat Commun,2015,6:5901.
[16] Germing U,Lauseker M,Hildebrandt B,et al.Survival,prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q);a multicenter study[J].Leukemia,2012,26(6):1286-1292.
[17] Grossmann V,Bacher U,Haferlach C,et al.Acute erythroid leukemia(AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics[J].Leukemia,2013,27(9):1940-1943.
[18] Zhang MY,Churpek JE,Keel SB,et al.Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy[J].Nat Genet,2015,47(2):180-185.
[19] West AH,Godley LA,Churpek JE.Familial myelodysplastic syndrome/acute leukemia syndromes:a review and utility for translational investigations[J].Ann N Y Acad Sci,2014,1310:111-118.
[20] Bejar R,Stevenson K,Abdel-Wahab O,et al.Clinical effect of point mutations in myelodysplastic syndromes[J].N Engl J Med,2011,364(26):2496-2506.
[21] Papaemmanuil E,Gerstung M,Malcovati L,et al.Clinical and biological implications of driver mutations in myelodysplastic syndromes[J].Blood,2013,122(22):3616-3627;quiz3699.
[22] Haferlach T,Nagata Y,Grossmann V,et al.Landscape of genetic lessions in 944 patients with myelodysplastic syndromes[J].Leukemia,2014,28(2):241-247.
[23] Bejar R,Stevenson KE,Caughey B,et al.Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoitic stem cell transplantation[J].J Clin Oncol,2014,32(25):2691-2698.
[24] Traina F,Visconte V,Elson P,et al.Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms[J].Leukemia,2014,28(1):78-87.
[25] Bejar R,Lord A,Stevenson K,et al.TET2 mutations predict response to hypomethylating agents in myelodyplastic syndrome patients[J].Blood,2014,124(17):2705-2712.
[26] Bally C, Ades L,Renneville A,et al.Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine[J].Leuk Res,2014,38(7):751-755.
[27] Haferlach T,Nagata Y,Grossmann V,et al.Landscape of genetic lesions in 944 patients with myelodysplastic syndromes[J].Leukemia,2014,28(2):241-247.
[28] Jabbour EJ,Garcia-Manero G,Strati P,et al.Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure:a report on behalf of the MDS Clinical Research Consortium[J].Cancer,2015,121(6):876-882.
[29] Prebet T,Gore SD,Esterni B,et al.Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure[J].J Clin Oncol,2011,29(24):3322-3327.
[30] Sekeres MA,Tiu RV,Komrokji R,et al.Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes[J].Blood,2012,120(25):4945-4951.
[31] Sekeres MA,Giagounidis A,Kantarjian H,et al.Development and validation of a model to predict platelet response to romiplostim in patients with low-risk myelodysplastic syndromes[J].Br J Haematol,2014,167(3):337-345.
[32] Platzbecker H,Germing U,Giagounidis A,et al.ACE-536 increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes(MDS):preliminary results from a phase 2 study[J].Blood,2014,124:411.
[33] Silverman LR,Greenberg P,Raza A,et al.Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy[J].Hematol Oncol,2015,33(2):57-66.
[34] Ortmann CA,Kent DG,Nangalia J,et al.Effect of mutation order on myeloproliferative neoplasms[J].N Engl J Med,2015,372:601-612.
[35] Vannucchi A,Guglielmelli P,Rotunno G,et al.Mutation-enhanced international prognostic scoring system(MIPSS) for primary myelofibrosis:an AGIMM & IWG-MRT project[J].Blood,2014,124(21):405.
[36] Tefferi A,Guglielmelli P,Finke C,et al.Integration of mutations and karyotype towards a genetics-based prognostic scoring system(GPSS) for primary myelofibrosis[J].Blood,2014,124(21):406.

2015年髓系肿瘤研究进展

Research advances of myeloid neoplasmas in 2015

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘丽丽, 袁宇婷, 赖耿良, 田川, 蓝翔, 叶中绿. 儿童急性淋巴细胞白血病第15天微小残留与预后的关系[J]. 临床荟萃, 2024, 39(1): 47-52.
[2]	董整荣, 陶千山, 沈元元, 董毅. 163例急性早幼粒细胞白血病患者随访结果分析[J]. 临床荟萃, 2023, 38(9): 813-818.
[3]	杜佳宜, 刘丽丽, 何永忠, 田川, 蓝翔, 叶中绿. 儿童急性淋巴细胞白血病化疗期间严重不良事件临床观察[J]. 临床荟萃, 2023, 38(2): 149-154.
[4]	王壮壮, 刘彦廷, 田春雷, 任欢, 艾文兵. 长链非编码RNA在胶质瘤中的研究进展[J]. 临床荟萃, 2023, 38(11): 1053-1056.
[5]	陈璨, 黄永芬, 苗雨青. 老年急性髓样白血病的治疗进展[J]. 临床荟萃, 2023, 38(10): 954-960.
[6]	张月月, 谢美芳, 孙艮. 类风湿关节炎合并T-细胞大颗粒淋巴细胞白血病1例及文献复习[J]. 临床荟萃, 2022, 37(8): 728-732.
[7]	尹玲玲, 吴文健, 朱锋. 急性髓系白血病转换为急性淋巴细胞白血病1例并文献复习[J]. 临床荟萃, 2022, 37(11): 1025-1030.
[8]	刘建宁, 孙立, 牛志云, 温树鹏, 王颖, 张学军, 王福旭. PD-1在急性白血病异基因造血干细胞移植后T淋巴细胞的表达[J]. 临床荟萃, 2021, 36(3): 251-255.
[9]	黄嘉惠, 叶中绿. 儿童白血病合并多重耐药菌感染的研究进展[J]. 临床荟萃, 2021, 36(2): 188-192.
[10]	沈子园, 康海全, 桑威, 闫冬梅. 白血病合并感染患者细菌分布、耐药情况及死亡危险因素分析[J]. 临床荟萃, 2021, 36(12): 1092-1096.
[11]	马瑞, 孙于谦. 单倍型相合移植规范化治疗急性白血病[J]. 临床荟萃, 2021, 36(10): 869-873.
[12]	卢文艺, 赵明峰. 急性淋巴细胞白血病的规范治疗[J]. 临床荟萃, 2021, 36(10): 874-879.
[13]	刘巧雪, 魏辉. 急性髓细胞白血病的规范化治疗[J]. 临床荟萃, 2021, 36(10): 880-883.
[14]	秦亚溱. 慢性髓性白血病患者BCR-ABL融合基因的规范化检测及临床应用[J]. 临床荟萃, 2021, 36(10): 884-888.
[15]	王卉, 陈曼. 流式细胞术检测急性髓系白血病微小残留病的现状与进展[J]. 临床荟萃, 2021, 36(10): 889-895.